



**hVIVO plc**  
**("hVIVO" or the "Company")**

**Director dealings**

hVIVO plc (AIM & Euronext: HVQ) (formerly Open Orphan plc) announces that it has received notification that Yamin 'Mo' Khan, Chief Executive Officer of the Company, yesterday acquired 13,526 ordinary shares of 0.1 pence each in the capital of the Company as a result of a dividend reinvestment plan. Following the purchase of shares Mo holds 523,730 ordinary shares representing approximately 0.08 per cent of the Company's issued ordinary capital.

**For further information please contact:**

<b>hVIVO plc</b> Yamin 'Mo' Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer	+44 (0) 20 7756 1300
<b>Liberum Capital (Nominated Adviser and Joint Broker)</b> Ben Cryer, Edward Mansfield, Phil Walker, Will King	+44 (0) 20 3100 2000
<b>finnCap plc (Joint Broker)</b> Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)	+44 (0) 20 7220 0500
<b>Davy (Euronext Growth Adviser and Joint Broker)</b> Anthony Farrell, Niall Gilchrist	+353 (0) 1 679 6363
<b>Walbrook PR (Financial PR &amp; IR)</b> Stephanie Cuthbert / Phillip Marriage / Louis Ashe-Jepson	+44 (0) 20 7933 8780 or hvivo@walbrookpr.com +44 (0) 7796 794 663 / +44 (0) 7867 984 082 / +44 (0) 7747 515 393

**Notes to Editors**

**About hVIVO**

hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Company has world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capability via its [FluCamp](#) volunteer screening facilities in London and Manchester.

**Notification of transactions by Directors, Persons Discharging Managerial Responsibilities ("PDMRs") and**

persons closely associated with them.

<b>1.</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>	
a)	Name	Yamin Khan
<b>2.</b>	<b>Reason for the Notification</b>	
a)	Position/status	Chief Executive Officer
b)	Initial notification/amendment	Initial notification
<b>3.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	hVIVO plc
b)	LEI	213800VT5KBM7JLIV118
<b>4.</b>	<b>Details of the transaction(s):section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted</b>	
a)	Description of the Financial instrument, type of instrument	Ordinary shares of 0.1 pence each
	Identification code	ESVUFR ISIN GB00B9275X97
b)	Nature of the Transaction	Purchase of ordinary shares pursuant to a dividend reinvestment plan
c)	Price(s) and volume(s)	Price
		Volume
		16.97 pence
		13,526
d)	Aggregated information - Aggregated volume - Price	As above
e)	Date of the transaction	13/06/2023
f)	Place of the transaction	London Stock Exchange

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFZGMVLFKGFZM